Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/35473583http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/35473583http://www.w3.org/2000/01/rdf-schema#comment"

Background

To explore the expression and carcinogenic mechanism of RIPK2 in human tumours, and to provide the theoretical basis for the further study of RIPK2.

Methods

We used the TCGA, CPTAC, HPA databases to analyse the expression, mutation, and prognosis of RIPK2 in human tumours. Through the Cbioportal, Ualcan, TIMER2.0, and STRING websites, We understand the genetic variation, immune infiltration and enrichment analysis of RIPK2 related genes.

Results

RIPK2 was highly expressed in most tumours (such as BRCA, COAD and LUSC, etc.), and the high expression of RIPK2 was correlated with tumour stage and prognosis. In addition, Amplification was the main type of RIPK2 in tumour mutation state, and the amplification rate was about 8.5%. In addition, RIPK2 was positively associated with tumour-infiltrating immune cells (such as CD8+ T, Tregs, and cancer-associated fibroblasts). According to the KEGG analysis, RIPK2 may play a role in tumour mainly through NOD-like signaling pathway and NF-kappaB signaling pathway. GO enrichment analysis showed that the RIPK2 is mainly related to I-kappaB kinase/NF-kappaB signaling, Ribonucleoprotein granule and Ubiquitin-like protein ligase binding.

Conclusion

RIPK2 plays an important role in the occurrence, development and prognosis of malignant tumours. Our pancancer study provided a relatively comprehensive description of the carcinogenic effects of RIPK2 in different tumours, and provided useful information for further study of RIPK2."xsd:string
http://purl.uniprot.org/citations/35473583http://purl.org/dc/terms/identifier"doi:10.1186/s12920-022-01239-3"xsd:string
http://purl.uniprot.org/citations/35473583http://purl.uniprot.org/core/author"Liu R."xsd:string
http://purl.uniprot.org/citations/35473583http://purl.uniprot.org/core/author"Ma Y."xsd:string
http://purl.uniprot.org/citations/35473583http://purl.uniprot.org/core/author"Luo H."xsd:string
http://purl.uniprot.org/citations/35473583http://purl.uniprot.org/core/author"Zhang Q."xsd:string
http://purl.uniprot.org/citations/35473583http://purl.uniprot.org/core/author"Zhang H."xsd:string
http://purl.uniprot.org/citations/35473583http://purl.uniprot.org/core/author"Wang X."xsd:string
http://purl.uniprot.org/citations/35473583http://purl.uniprot.org/core/date"2022"xsd:gYear
http://purl.uniprot.org/citations/35473583http://purl.uniprot.org/core/name"BMC Med Genomics"xsd:string
http://purl.uniprot.org/citations/35473583http://purl.uniprot.org/core/pages"97"xsd:string
http://purl.uniprot.org/citations/35473583http://purl.uniprot.org/core/title"A pancancer analysis of the carcinogenic role of receptor-interacting serine/threonine protein kinase-2 (RIPK2) in human tumours."xsd:string
http://purl.uniprot.org/citations/35473583http://purl.uniprot.org/core/volume"15"xsd:string
http://purl.uniprot.org/citations/35473583http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/35473583
http://purl.uniprot.org/citations/35473583http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/35473583
http://purl.uniprot.org/uniprot/#_A0A0S2Z4Z8-mappedCitation-35473583http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35473583
http://purl.uniprot.org/uniprot/#_B3KQM3-mappedCitation-35473583http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35473583
http://purl.uniprot.org/uniprot/#_E7ERW9-mappedCitation-35473583http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35473583
http://purl.uniprot.org/uniprot/#_Q2TU65-mappedCitation-35473583http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35473583
http://purl.uniprot.org/uniprot/#_O43353-mappedCitation-35473583http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35473583
http://purl.uniprot.org/uniprot/#_Q6Q322-mappedCitation-35473583http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35473583
http://purl.uniprot.org/uniprot/Q2TU65http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/35473583
http://purl.uniprot.org/uniprot/O43353http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/35473583
http://purl.uniprot.org/uniprot/E7ERW9http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/35473583
▶